TY - JOUR
T1 - PERISCOPE
T2 - road towards effective control of pertussis
AU - The PERISCOPE Consortium
AU - Diavatopoulos, Dimitri A.
AU - Mills, Kingston H.G.
AU - Kester, Kent E.
AU - Kampmann, Beate
AU - Silerova, Marcela
AU - Heininger, Ulrich
AU - van Dongen, Jacques J.M.
AU - van der Most, Robbert G.
AU - Huijnen, Martijn A.
AU - Siena, Emilio
AU - Mielcarek, Nathalie
AU - Ochs, Martina M.
AU - Denoël, Philippe
AU - Berbers, Guy
AU - Buisman, Annemarie M.
AU - de Jonge, Marien I.
AU - Fenwick, Craig
AU - Gorringe, Andrew
AU - He, Qiushui
AU - Kelly, Dominic
AU - Le Grand, Roger
AU - Locht, Camille
AU - Mascart, Françoise
AU - Mertsola, Jussi
AU - Orfao, Alberto
AU - Pantaleo, Giuseppe
AU - Pollard, Andrew J.
AU - Preston, Andrew
AU - Read, Robert
AU - Sebo, Peter
AU - van Els, Cecile
AU - Vecerek, Branislav
AU - Londoño-Hayes, Patricia
AU - de Groot, Ronald
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/5
Y1 - 2019/5
N2 - The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
AB - The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
UR - https://www.scopus.com/pages/publications/85065499882
U2 - 10.1016/S1473-3099(18)30646-7
DO - 10.1016/S1473-3099(18)30646-7
M3 - Review article
C2 - 30503084
AN - SCOPUS:85065499882
SN - 1473-3099
VL - 19
SP - e179-e186
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 5
ER -
